Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
    • Topics A-Z
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
    • Topics A-Z
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Articles
  • Issues

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Genetics
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues

Share

August 2016; 2 (4) Clinical/Scientific NotesOpen Access

Progressive brain calcifications and signs in a family with the L9R mutation in the PDGFB gene

Martin Paucar, Håkan Almqvist, Ahmed Saeed, Gösta Bergendal, Jan Ygge, Staffan Holmin, Ingemar Björkhem, Per Svenningsson
First published July 6, 2016, DOI: https://doi.org/10.1212/NXG.0000000000000084
Martin Paucar
From the Department of Neurology (M.P., P.S.), Department of Neuroradiology (H.A., S.H.), Karolinska University Hospital; Department of Clinical Neuroscience (M.P., H.A., J.Y., S.H., P.S.), Division of Clinical Chemistry, Department of Laboratory Medicine (A.S., I.B.), Department of Neuroimaging (G.B.), Karolinska Institutet, Stockholm, Sweden; Department of Biochemistry (A.S.), Faculty of Medicine, University of Khartoum, Sudan; and St. Erik Eye Hospital (J.Y.), Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Håkan Almqvist
From the Department of Neurology (M.P., P.S.), Department of Neuroradiology (H.A., S.H.), Karolinska University Hospital; Department of Clinical Neuroscience (M.P., H.A., J.Y., S.H., P.S.), Division of Clinical Chemistry, Department of Laboratory Medicine (A.S., I.B.), Department of Neuroimaging (G.B.), Karolinska Institutet, Stockholm, Sweden; Department of Biochemistry (A.S.), Faculty of Medicine, University of Khartoum, Sudan; and St. Erik Eye Hospital (J.Y.), Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahmed Saeed
From the Department of Neurology (M.P., P.S.), Department of Neuroradiology (H.A., S.H.), Karolinska University Hospital; Department of Clinical Neuroscience (M.P., H.A., J.Y., S.H., P.S.), Division of Clinical Chemistry, Department of Laboratory Medicine (A.S., I.B.), Department of Neuroimaging (G.B.), Karolinska Institutet, Stockholm, Sweden; Department of Biochemistry (A.S.), Faculty of Medicine, University of Khartoum, Sudan; and St. Erik Eye Hospital (J.Y.), Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gösta Bergendal
From the Department of Neurology (M.P., P.S.), Department of Neuroradiology (H.A., S.H.), Karolinska University Hospital; Department of Clinical Neuroscience (M.P., H.A., J.Y., S.H., P.S.), Division of Clinical Chemistry, Department of Laboratory Medicine (A.S., I.B.), Department of Neuroimaging (G.B.), Karolinska Institutet, Stockholm, Sweden; Department of Biochemistry (A.S.), Faculty of Medicine, University of Khartoum, Sudan; and St. Erik Eye Hospital (J.Y.), Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Ygge
From the Department of Neurology (M.P., P.S.), Department of Neuroradiology (H.A., S.H.), Karolinska University Hospital; Department of Clinical Neuroscience (M.P., H.A., J.Y., S.H., P.S.), Division of Clinical Chemistry, Department of Laboratory Medicine (A.S., I.B.), Department of Neuroimaging (G.B.), Karolinska Institutet, Stockholm, Sweden; Department of Biochemistry (A.S.), Faculty of Medicine, University of Khartoum, Sudan; and St. Erik Eye Hospital (J.Y.), Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Staffan Holmin
From the Department of Neurology (M.P., P.S.), Department of Neuroradiology (H.A., S.H.), Karolinska University Hospital; Department of Clinical Neuroscience (M.P., H.A., J.Y., S.H., P.S.), Division of Clinical Chemistry, Department of Laboratory Medicine (A.S., I.B.), Department of Neuroimaging (G.B.), Karolinska Institutet, Stockholm, Sweden; Department of Biochemistry (A.S.), Faculty of Medicine, University of Khartoum, Sudan; and St. Erik Eye Hospital (J.Y.), Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingemar Björkhem
From the Department of Neurology (M.P., P.S.), Department of Neuroradiology (H.A., S.H.), Karolinska University Hospital; Department of Clinical Neuroscience (M.P., H.A., J.Y., S.H., P.S.), Division of Clinical Chemistry, Department of Laboratory Medicine (A.S., I.B.), Department of Neuroimaging (G.B.), Karolinska Institutet, Stockholm, Sweden; Department of Biochemistry (A.S.), Faculty of Medicine, University of Khartoum, Sudan; and St. Erik Eye Hospital (J.Y.), Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Per Svenningsson
From the Department of Neurology (M.P., P.S.), Department of Neuroradiology (H.A., S.H.), Karolinska University Hospital; Department of Clinical Neuroscience (M.P., H.A., J.Y., S.H., P.S.), Division of Clinical Chemistry, Department of Laboratory Medicine (A.S., I.B.), Department of Neuroimaging (G.B.), Karolinska Institutet, Stockholm, Sweden; Department of Biochemistry (A.S.), Faculty of Medicine, University of Khartoum, Sudan; and St. Erik Eye Hospital (J.Y.), Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Progressive brain calcifications and signs in a family with the L9R mutation in the PDGFB gene
Martin Paucar, Håkan Almqvist, Ahmed Saeed, Gösta Bergendal, Jan Ygge, Staffan Holmin, Ingemar Björkhem, Per Svenningsson
Neurol Genet Aug 2016, 2 (4) e84; DOI: 10.1212/NXG.0000000000000084

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
403

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Primary familial brain calcifications (PFBC) are a heterogeneous group of rare autosomal dominant disorders. Mutations in the PDGFB gene are the second most common cause of PFBC. A model for PDGFB-associated PFBC, hypomorphic PDGFBret/ret mouse, displays impaired blood-brain barrier (BBB), progressive brain calcifications and increased flux of the oxysterol 24S-hydroxycholesterol from the brain into the circulation.1,2 Only 8 families and 2 sporadic cases with PDGFB mutations have been identified so far, one of them a Swedish-Finnish family previously described as F13.1,3,–,6 Very little is known about the natural history of PDGFB-associated PFBC. Here, we provide a comprehensive long-term follow-up of the F13 family.

Methods.

The study was approved by the local ethics committee. The F13 family harbors the c.26T>G (L9R) mutation in the PDGFB gene1 (pedigree in figure e-1 at Neurology.org/ng). Participants consented to physical examination, cognitive assessment, radiologic studies, and biochemical analyses. Biomarkers for neuronal and BBB damage in plasma and CSF, including oxysterols, were analyzed at a single point.

Imaging.

Dual-energy computed scans and brain MRIs were performed according to details provided in appendix e-1. The degree of calcification was measured with the Total Calcification Score (TCS).3 We also used software for image coregistration (Integrated Registration, GE AW server). In brief, the region of interest placed on the baseline CT is propagated in a semiautomated fashion to the follow-up examinations. Changes in Hounsfield units are measured as relative and absolute values.

Results.

The progression of clinical and radiologic features is summarized in appendix e-1. Mean time of clinical follow-up was 5.5 years, and the time between 2 successive brain CT scans was 4.8 years.

Clinical features.

In brief, all the affected had a diagnosis of migraine with aura and displayed subtle movement disorders and mild eye movement abnormalities. Patient III:1, the proband, was diagnosed with mild language impairment (anomia, paraphasias, and impaired repetition ability) and cognitive deficits (reduced working memory) and has developed chorea and posturing. Her father, II:3, has developed mild motor features and impaired tandem gait. Patient III:2 has a history of mixed substance abuse; he did not progress radiologically but has progressive chorea. Patient III:3 has mild postural tremor, chorea, and significant cognitive impairment (anomia, visuospatial deficits, reduced working memory and information processing speed). The main phenotype features are displayed in videos 1–4 and summarized in tables e-1 to e-4.

Imaging.

Patient II:3 has calcifications in the lentiform nucleus and in the white matter. The 3 patients in generation III have widespread calcifications in the basal ganglia (lentiform and caudate nuclei) along with varying degrees of calcifications in the thalamus, dentate nucleus, and white matter (figure 1, figures e-1 to e-3, tables e-5 to e-9). Two patients have cortical calcifications (III:1 and III:3). Using the TCS, we detected progression in 2 cases (III:1 and III:3), whereas the coregistration method detected progression in 3 patients (II:3, III:1, and III:3). An estimation of hydroxyapatite concentration in calcified areas is displayed in figure e-4.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1 Progressive calcifications in a family with the L9R mutation in the PDGFB gene

Density progression, as measured by change in Hounsfield units (HU), of calcifications in cerebellum, thalamus, basal ganglia, and frontal white matter in patient III:1. To the left axial (A.a and B.a) and sagittal sections (C.a) from the first CT scan done in 2009 and to the right sections performed in 2014 (A.b, B.b, and C.b). The sagittal sections display the right hemispheres of the brain and cerebellum (C.a and C.b). According to the TCS method, using the axial image could score the white matter changes as “moderate” but seem to be “severe” in the sagittal image. In the white matter (B.a and B.b), the HU increased by 142% or 124 HU, but the TCS remained unchanged at 3 points. In the lentiform nucleus (B.a and B.b), the HU increased by 29% or 70 HU, but the TCS remained also unchanged at 5 points. In the thalamus (B.a and B.b), the HU increased by 22% or 11 HU, but the TCS increased from 2 to 3 points. In the cerebellum (A.a and A.b), the HU increased by 44% or 17 HU and also increased in TCS from 2 to 3 points (for more details see table e-8).

Biochemistry.

We obtained CSF from 3 patients with patient III:2 having an elevated albumin CSF/serum ratio and patient III:3 elevated levels of neurofilament light chain (NfL) in the CSF. Oxysterol levels were nevertheless normal in all the examined participants (table e-10).

Discussion.

Brain calcifications are progressive in 3 individuals from the L9R family. All the 4 participants display some degree of subtle but progressive motor features and mild eye movement abnormalities. Chorea emerged in 2 patients of generation III (III:1 and III:3) and was progressive in another (III:2). Besides chorea, patient III:1 had a mild language impairment and reduced working memory. Patient III:3 has greater cognitive deficits than the index case (III:1).

Progressive calcifications are mentioned in only one previous PDGFB mutation5; however, TCS was not provided. The progressive features and elevated CSF-NfL level in one of the cases support the notion that PDGFB-associated PFBC is a neurodegenerative disease. Unexpectedly, only 1 of the 3 patients had signs of an affected BBB. Likewise, the CSF level of the steroid acid 7α-hydroxyl-3-oxo-4-cholestenoic acid, a putative marker of increased BBB permeability, was normal in all the 3 patients. This is in contrast with the results in the hypomorphic PDGFBret/ret mouse.2 Recent work in this model has demonstrated a more intact BBB in areas prone to calcifications.7

The coregistration method we tested here found evidence of progression in 3 patients and the TCS method in 2. Overcoming the ceiling effect of TCS is the main advantage of coregistration. Small sample size is the main limitation of our longitudinal follow-up.

Two levels of penetrance exist in PFBC: one radiologic and one clinical. The radiologic penetrance in PDGFB mutations is high, but, despite calcifications, some individuals are asymptomatic. Reduced clinical penetrance has been reported in 3 other PDGFB mutations despite the presence of brain calcifications (table e-11).

When brain calcifications will appear and whether their progression will plateau is unknown. Future work has to determine whether our findings can be generalized to other cases of PDGFB-associated PFBC or other forms of PFBC.

Acknowledgments

Acknowledgment: The authors thank all participants, Dr. Ruth H. Walker, Dr. Erik Jensen, and speech therapist Liv Thalén.

Footnotes

  • Supplemental data at Neurology.org/ng

  • Author contributions: Dr. Paucar, Dr. Almqvist, Prof. Holmin, Prof. Ygge, and Med Dr. Bergendahl: study concept, data collection, and writing of the manuscript. Dr. Paucar wrote the first draft. Dr. Almqvist performed the radiologic evaluation. Prof. Björkhem and Dr. Saeed performed the oxysterol analyses and edited the manuscript. Prof. Svenningsson: study concept and editing of the manuscript.

  • Study funding: Stockholm County Council. Martin Paucar was supported by the Stockholm County Council (combined clinical residency and PhD training program).

  • Disclosure: Dr. Paucar has received research support from the Stockholm County Council. Dr. Almqvist, Dr. Saeed, and Dr. Bergendal report no disclosures. Dr. Ygge has served on the editorial board of Acta Ophthalmologica. Dr. Holmin has served on the scientific advisory boards of 2 companies not related to this study, holds a patent for Endolumina medical access device, has received research support from Astra Zeneca, holds a stock option for Smartwise Sweden AB, and has received royalty payments for potential future sales of products from Smartwise Sweden AB. Dr. Björkhem reports no disclosures. Dr. Svenningsson has served on the scientific advisory board of CBD Solutions AB, has served on the editorial board of PLoS One, and has received research support from the Swedish Research Council and ALF Stockholm. Go to Neurology.org/ng for full disclosure forms. The Article Processing Charge was paid by the authors.

  • Received May 3, 2016.
  • Accepted in final form June 2, 2016.
  • © 2016 American Academy of Neurology

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

References

  1. 1.↵
    1. Keller A,
    2. Westenberger A,
    3. Sobrido MJ, et al.
    Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice. Nat Genet 2013;45:1077–1082.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Nicolas G,
    2. Pottier C,
    3. Charbonnier C, et al.
    Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification. Brain J Neurol 2013;136:3395–3407.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Nicolas G,
    2. Rovelet-Lecrux A,
    3. Pottier C, et al.
    PDGFB partial deletion: a new, rare mechanism causing brain calcification with leukoencephalopathy. J Mol Neurosci MN 2014;53:171–175.
    OpenUrlPubMed
  4. 4.↵
    1. Hayashi T,
    2. Legati A,
    3. Nishikawa T,
    4. Coppola G
    . First Japanese family with primary familial brain calcification due to a mutation in the PDGFB gene: an exome analysis study. Psychiatry Clin Neurosci 2015;69:77–83.
    OpenUrl
  5. 5.↵
    1. Keogh MJ,
    2. Pyle A,
    3. Daud D, et al.
    Clinical heterogeneity of primary familial brain calcification due to a novel mutation in PDGFB. Neurology 2015;84:1818–1820.
    OpenUrlPubMed
  6. 6.↵
    1. Saeed AA,
    2. Genové G,
    3. Li T, et al.
    Effects of a disrupted blood-brain barrier on cholesterol homeostasis in the brain. J Biol Chem 2014;289:23712–23722.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Vanlandewijck M,
    2. Lebouvier T,
    3. Andaloussi Mäe M, et al.
    Functional characterization of germline mutations in PDGFB and PDGFRB in primary familial brain calcification. PLoS One 2015;10:e0143407.
    OpenUrlPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Topics Discussed

  • All Imaging
  • All Movement Disorders
  • All Genetics

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Article
    Neuroradiologic patterns and novel imaging findings in Aicardi-Goutières syndrome
    Roberta La Piana, Carla Uggetti, Federico Roncarolo et al.
    Neurology, November 18, 2015
  • Review
    Mechanisms of calcification in Fahr disease and exposure of potential therapeutic targets
    Melissa E.M. Peters, Esther J.M. de Brouwer, Jonas W. Bartstra et al.
    Neurology: Clinical Practice, December 23, 2019
  • Article
    Diagnostic accuracy of noncontrast CT imaging markers in cerebral venous thrombosis
    Pieter-Jan Buyck, Susanna M. Zuurbier, Carlos Garcia-Esperon et al.
    Neurology, January 18, 2019
  • Article
    Iron leakage owing to blood–brain barrier disruption in small vessel disease CADASIL
    Yuto Uchida, Hirohito Kan, Keita Sakurai et al.
    Neurology, June 25, 2020
Neurology Genetics: 9 (2)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Genetics | Online ISSN: 2376-7839

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise